Compare OCS & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCS | NMFC |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 972.8M |
| IPO Year | N/A | 2011 |
| Metric | OCS | NMFC |
|---|---|---|
| Price | $21.14 | $9.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $39.80 | $10.00 |
| AVG Volume (30 Days) | 100.6K | ★ 590.7K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 14.14% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.66 |
| Revenue | $991,999.00 | ★ $340,877,000.00 |
| Revenue This Year | $35.00 | N/A |
| Revenue Next Year | $874.12 | N/A |
| P/E Ratio | ★ N/A | $13.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.00 | $8.84 |
| 52 Week High | $23.08 | $12.05 |
| Indicator | OCS | NMFC |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 31.84 |
| Support Level | $19.12 | $9.47 |
| Resistance Level | $21.86 | $9.74 |
| Average True Range (ATR) | 0.73 | 0.14 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 75.93 | 3.66 |
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.